Basic Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Mar 7, 2018; 24(9): 971-981
Published online Mar 7, 2018. doi: 10.3748/wjg.v24.i9.971
Figure 1
Figure 1 Prevalence of clarithromycin-resistance according to cagA genotype. A: All patients; B: Treatment naïve patients; C: Previously treated patients.
Figure 2
Figure 2 Prevalence of clarithromycin resistance according to vacA genotype. A: All patients; B: Treatment naïve patients; C: Previously treated patients. Most virulent: S1/M1, S1/M2; Least virulent: S2/M1; S2/M2.
Figure 3
Figure 3 Prevalence of fluoroquinolone-resistance according to cagA genotype. A: All patients; B: Treatment naïve patients; C: Previously treated patients.
Figure 4
Figure 4 Prevalence of fluoroquinolone-resistance according to vacA genotype. A: All patients; B: Treatment naïve patients; C: Previously treated patients. Most virulent: S1/M1, S1/M2; Least virulent: S2/M1; S2/M2.